Short Communication

Encapsulated Salmon Polar Lipids Modestly Reduce Postprandial Platelet Sensitivity to PAF and Thrombin in Healthy Adults: A Pilot Study.

Ronan Lordan [1,2,3,4,†,*], Alexandros Tsoupras [1,5,†], Phil Jakeman [6], and Ioannis Zabetakis [1,2,*]

[1] Bernal Institute, University of Limerick, V94 T9PX, Limerick, Ireland.

[2] Department of Chemistry, University of Limerick, V94 T9PX, Limerick, Ireland.

[3] School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, D02 VN51 Dublin, Ireland.

[4] FutureNeuro Research Ireland Centre for Translational Brain Science, RCSI University of Medicine & Health Sciences, D02 YN77 Dublin, Ireland.

[5] Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Democritus University of Thrace, Kavala University Campus, St. Lucas, 65404 Kavala, Greece.

[6] Department of Physical Education and Sport Sciences, University of Limerick, V94 T9PX, Limerick, Ireland.

[*] Correspondence: ronanlordan@rcsi.com

[†] These authors contributed equally to this research.

Abstract:

The postprandial effects of a novel food-grade extracted salmon polar lipids (SPL) supplement against platelet-activating factor (PAF) and thrombin-induced platelet aggregation in a human pilot study was evaluated. This study was double-blinded, crossover, and placebo controlled in design. Five healthy volunteers completed 4 h time-course trials on 5 separate days. Blood was drawn at baseline before subjects consumed a standardized breakfast with one of the following treatments: a low-dose (0.25 g) or a high-dose (0.5 g) of SPL encapsulated within a stomach resistant capsule (LDSR and HDSR respectively) or a non-resistant capsule (LDSNR and HDSNR, respectively), or placebo capsules containing food-grade glycerin (0.5 g; Placebo). Blood was analyzed at 1 h intervals for 4 h. A significant reduction of platelet sensitivity occurred after 3 h against PAF EC_{50} in the HDSNR trial and after 4 h against thrombin EC_{50} in the LDSNR trial when EC_{50} values were adjusted for placebo. Plasma levels of glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, fibrinogen, pro-thromboplastin time, and activated partial thromboplastin time remained unaffected. In conclusion, this pilot study determined that a novel SPL supplement exhibits promising antiplatelet properties postprandially by modestly improving platelet sensitivity against both the PAF and thrombin pathways.

Keywords: polar lipids; platelet function; platelet-activating factor; thrombin; nutraceuticals; fish oil; postprandial; haemostasis; salmon oil; postprandial

46 **1. Introduction**

47 Low-grade or systemic inflammation contributes to the onset of atherosclerosis and
48 subsequent cardiovascular diseases (CVD) [1-4]. Activation and aggregation of platelets contribute
49 to the 'crosstalk' between various cells including endothelial cells and leukocytes engaged in the
50 inflammatory development of atherosclerosis and atherothrombotic events [5-7]. Platelet agonists
51 mediate platelet activation and aggregation. Of these, platelet-activating factor (PAF) and
52 thrombin are among the most potent [5,8,9]. PAF activates various pathophysiological signaling
53 pathways in response to inflammatory stimuli that negatively affect cardiovascular risk factors
54 [10,11]. Thrombin on the other hand, is a procoagulant and pro-inflammatory serine protease that
55 participates in coagulant catalytic processes as well as the activation of other cell types in several
56 pathophysiological processes [8,9,12], including atherosclerosis [12]. PAF and thrombin are known
57 to enhance the expression of cell adhesion molecules that induce secretion of pro-inflammatory
58 cytokines, an inflammatory response in atherosclerotic plaques, proliferation of aortic smooth
59 muscle cells and vascular lesion at sites of injury [2,12,13].

60 The inhibition of PAF and thrombin related pathways offers a potential therapeutic strategy
61 to target thrombosis and inflammatory responses that underpin the atherosclerosis and
62 inflammatory disorders [2,13,14]. It is recognized that some dietary patterns and their components
63 have the potential to reduce levels of specific risk factors for CVD, including the reduction of
64 inflammation [15,16]. CVD-related PAF and thrombin pathways are affected by the diet either
65 favorably, by positive dietary behaviors such as those attributed to the Mediterranean diet, or
66 detrimentally by dietary behavior related to the Western diet [17]. The Western diet is characterized
67 by energy-rich, ultra-processed foods that cause exaggerated postprandial increases in plasma
68 lipids and glucose leading to hyperglycemia and hyperlipidemia [18]. These elevations lead to

excess pro-inflammatory reactions and activated platelets and immune cells [19,20]. Indeed, postprandial platelet activation and hypercoagulability are major risk factors for CVD [21], of which the PAF pathway can be modulated by dietary components postprandially [22].

Fish oils, particularly omega-3 polyunsaturated fatty acids (n-3 PUFA) have been a promising but contentious area of research due to their putative cardioprotective effects [23,24]. Food-grade extracts from sustainable sources are potential candidates for the development of novel cardioprotective nutraceuticals, which are important for improving underlying health conditions and overall well-being in aging populations characterized by increased risk of non-communicable diseases [25,26]. In previous studies, it has been demonstrated that polar lipids extracted from Irish organic farmed salmon (*Salmo salar*) possess strong antithrombotic properties against platelet aggregation *in vitro* relating to the PAF and thrombin pathways *in vitro* [25,27,28]. Studies have also shown that salmon oil may favorably affect metabolic syndrome through phospholipid remodeling, inhibiting insulin resistance, and reducing inflammatory factors [29]. Indeed, the consumption of fish and fish oil supplements may affect platelet function and cardiovascular health [30-32], although there is a dearth of postprandial investigations assessing the biological effects of marine-sourced polar lipids. This pilot study investigates the temporal pattern and magnitude of the antiplatelet effects of food-grade extracted salmon polar lipid ingestion (SPL) postprandially in a pilot study of five healthy human subjects over a 4 h period.

2. Materials and Methods

2.1. Materials and instrumentation

All glass and plastic consumables, reagents, and solvents were of analytical grade and were purchased from Fisher Scientific Ltd (Dublin, Ireland). 18G Insyte™ cannulas were purchased

92 from Becton Dickinson Ltd. (UK). A CARESITE® extension set, 0.9% w/v saline, and Omnifix®
93 syringes with varied volumes were purchased from Braun Medical Ltd. (Dublin, Ireland).
94 Tegaderm™ transparent protective dressings were acquired from 3M Health Care (Neuss,
95 Germany). Evacuated sodium citrate 9 NC, EDTA KE, glucose FE, and serum gel Z S-monovettes
96 for blood sampling were purchased from Sarstedt Ltd. (Wexford, Ireland). The *ex vivo* platelet
97 aggregation bioassay was carried out on a Chronolog-490 two channel turbidimetric platelet
98 aggregometer (Havertown, PA, USA), coupled to the accompanying AGGRO/LINK software
99 package. All platelet aggregation consumables were purchased from Labmedics LLP (Abingdon
100 on Thames, UK). Standard PAF, thrombin, and BSA were purchased from Sigma Aldrich Ltd.
101 (Wicklow, Ireland). Centrifugations were carried out on an Eppendorf 5702R centrifuge
102 (Eppendorf Ltd Stevenage UK). Spectrophotometric analysis was carried out on a Shimadzu UV-
103 1800 spectrophotometer (Kyoto, Japan).
104

105 *2.2. Isolation and encapsulation of food-grade SPL*

106 A sustainable marine source was chosen for these studies; Irish organic farmed salmon
107 (*Salmo salar*). Fresh salmon fillets were homogenized mechanically by blender and total lipids
108 (TL) extracted and further separated into neutral lipid (NL) and polar lipid fraction (SPL) in
109 accordance with EU legislation for food-grade based extractions of fish oil (consolidated Directive
110 2009/32/EC: https://eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX:32009L0032) as
111 previously described [25]. Solvents were evaporated from samples using flash rotary evaporation
112 and lipid samples transferred to small vials and remaining solvents evaporated under a stream of
113 nitrogen. The acquired SPL extracts were weighed and encapsulated under a stream of nitrogen
114 into gelatin-coated capsules of two types: stomach non-resistant capsules (SNR) and stomach

115 resistant capsules (SR). Placebo capsules were prepared containing only glycerin. All capsules
116 were prepared external (Propak Health Ltd., Finglas, Dublin, Ireland) to the university and were
117 tested for microbial safety, heavy metals, pesticides, and various other potentially harmful
118 constituents (Eurofins Food Testing Ireland Ltd., Dungarvan, Co. Waterford, Ireland).
119

120 *2.3. Study population*

121 This study was conducted according to the guidelines laid down in the Declaration of
122 Helsinki, approved by the Ethics Committee of the Faculty of Science and Engineering of the
123 University of Limerick and registered with ClinicalTrials.gov NCT03603769. Following written
124 and informed consent, six participants completed a routine clinical, haematological, biochemical,
125 and anthropometrical screening session with a general practitioner to assess suitability. Exclusion
126 criteria were smoking, following a diet regime or special diet, diagnosis of hypertension, metabolic
127 or endocrine disease, gastrointestinal disorders, blood clotting disorders, dyslipidaemia, or a recent
128 history of medical or surgical events. One volunteer that initially participated and was deemed
129 eligible for the study had to terminate their participation due to personal commitments. A total of
130 five participants (n = 5) completed all aspects of the study. Recruitment, screening, and treatment
131 allocation occurred as outlined in the CONSORT flow diagram (Figure 1). The baseline
132 characteristics of the five participants are provided in Table 1 and Table 2 in the supplementary
133 files. Healthy participants were selected for this pilot study for several reasons, including safety
134 assessment and tolerability of an acute dose of the supplement before testing in a clinical
135 population. Furthermore, this approach allowed for assessment of the capsule under controlled
136 baseline physiology in participants with stable platelet profiles in the absence of medication, which

would allow for more clear detection of physiological changes directly attributable to the intervention.



Fig. 1. CONSORT flow diagram of participant involvement and trial layout

150 *2.4. Study protocol*

151 In a randomized, double-blind design, each subject completed five trials on separate days
152 at least 14 days apart from each other. Three days before the trial and throughout the entire trial
153 period, volunteers were instructed to follow Irish national dietary guidelines [33], which allows
154 moderate consumption of fish (once or twice per week). The participants were asked to abstain
155 from alcohol, avoid excessive exercise, and sleep at least 7 h/day throughout the study. After
156 fasting overnight (10–12 h), each participant arrived at the laboratory at 09:00 and were seated in
157 a phlebotomy chair and allowed to rest for five minutes. A certified clinical nurse then proceeded
158 to fit the volunteer with a cannula. A 20 G cannula (BD Insyte™) was inserted into the median
159 cubital vein, which was attached to a CARESITE® extension set. The cannula was held in place
160 with a Tegaderm™ transparent protective dressing.

161 An initial 1.5 mL of blood was drawn through the cannula using a 3 mL syringe. This was
162 discarded to fill the line with blood. A further 21.4 mL of blood was drawn using a 25 mL
163 Omnifix® syringe. The line was then flushed with 10 mL of 0.9% w/v saline using a 10 mL
164 Omnifix® syringe. The collected blood was then transferred into 5 S-monovettes: 1) 8.2 mL
165 sodium citrate 9 NC S-monovette; 2) 2.9 mL sodium citrate 9 NC S-monovette; 3) 2.7 mL EDTA
166 KE S-monovette; 4) 2.7 mL Glucose FE S-monovette; 5) 4.9 mL Serum Gel Z S-monovette
167 (Sarstedt Ltd., Wexford, Ireland). All monovettes were appropriately labelled and placed in
168 clinical sample transportation boxes in order to be sent to the appropriate laboratory for further
169 analysis; monovette 1 from each participant was immediately sent to the laboratories of the
170 Department of Biological Sciences of UL for analysis, while monovettes 2-5 were kept in the
171 transportation box and sent to the Haematology and Biochemistry Laboratory of University
172 Hospital Limerick for analysis immediately after the 5th and final blood draw.

173 Following the initial baseline blood draw at approximately 09.05, the participant was fed a
174 standardized breakfast, namely porridge, which was made with boiling water as per the
175 manufacturer's instructions (Flahavan's Quick Oats® original with the following nutritional value:
176 Energy 637 kJ/ 150 kcal; Fat 2.6 g; of which saturated 0.4 g; Carbohydrates 25 g; of which sugars
177 7.3 g; Fibre 3.5 g; Protein 5.2 g; Salt 0.03 g).

178 Once breakfast was consumed, randomized and double-blind administration of capsules of
179 different types and dose, according to the aforementioned trials design took place. Each capsule
180 was administered with a glass of water. The capsule compositions were as follows:

181 (1) LDSNR, low-dose stomach non-resistant capsule containing 0.25 g of SPL

182 (2) HDSNR, high-dose stomach non-resistant capsule contained 0.5 g of SPL

183 (3) LDSR, low-dose stomach resistant capsule contained 0.25 g of SPL

184 (4) HDSR, high-dose stomach resistant capsule contained 0.5 g of SPL

185 (5) Placebo stomach release capsule containing 0.5 g of food-grade glycerin

186 Blood samples were subsequently obtained by repeating the steps for blood sampling every
187 h for the next 4 h. The citrated blood samples were sent at each time of blood withdrawal to the
188 Department of Biological Sciences of UL for platelet aggregometry testing and the remaining
189 blood tubes were stored in a blood transportation box to be taken to the haematology and
190 Biochemistry laboratories of University Hospital Limerick, where several biological parameters
191 were assessed. After each blood draw, the cannula was flushed with saline (0.9 % w/v). During
192 the study, participants were encouraged to drink at least 50 mL of water following every blood
193 draw and were encouraged to keep their cannulated arm supported, still, and warm, while
194 remaining seated.

195 *2.3. Ex vivo human platelet-rich plasma (hPRP) aggregation assays*

196 The platelet aggregation response to PAF and thrombin was conducted as previously
197 described with some modifications [34]. Briefly, standard solutions of PAF and thrombin were
198 prepared ranging from 2.6 x 10^{-8} to 2.6 x 10^{-5} mol/L BSA (2.5 mg BSA/mL saline (0.9%)) PAF
199 and 0.01-0.4 U/mL active thrombin in saline (0.9%). hPRP was isolated from anticoagulated
200 (sodium citrate 0.106 mol/l) blood samples by centrifugation at 194 x g for 18 min at 24 °C, the
201 supernatant hPRP transferred to polypropylene tubes at room temperature. Platelet-poor plasma
202 (PPP) was obtained by further centrifugation at 1465 x g for 20 min at 24°C and supernatant PPP
203 transferred to polypropylene tubes at room temperature for aggregation bioassay. Then an
204 aggregation bioassay was conducted. Briefly, PPP (250 µL) and hPRP (250 µL) were pipetted into
205 separate glass aggregometer (Chronology, Havertown, PA, USA) cuvettes at 37 °C. Platelet
206 aggregation, detected by change in light transmission at a fixed wavelength (620 nm) in the
207 presence of increasing concentration of agonist generated aggregation curves from which the
208 concentration of agonist that induces maximum-reversible platelet aggregation could be
209 determined. The serial reduction of either PAF or thrombin required to induce maximum-
210 reversible platelet aggregation revealed a linear response between 20%-80% of maximum and the
211 concentration of agonist that induced 50% platelet aggregation, i.e., the EC_{50} value. The EC_{50} value
212 represented platelet sensitivity to the agonist. The higher the EC_{50} value the lower the sensitivity
213 of the platelet to the agonist to either PAF or thrombin.

214

215 *2.2. Biochemical and haematological measuements*

216 The University Hospital Limerick (Limerick, Ireland) undertook all biochemical and
217 haematological analyses. Chemiluminescent magnetic microparticle immunoassay (CMIA)

218 technology (Abbott Architect C16000 clinical chemistry analyser®, Abbott Ltd., Dublin, Ireland)
219 was employed to measure glucose, triglycerides (TG), total cholesterol (TC), high-density
220 lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and C-reactive
221 protein (CRP) in each blood sample. Prothrombin time (PT) activated partial thromboplastin time
222 (APTT), fibrinogen and the international normalized ratio (INR) were measured by
223 electromechanical detection (Stago STA-R Evolution® analyser, Diagnostica Stago, Wicklow,
224 Ireland).
225

226 *2.2. Statistical analysis*

227 This pilot study employed a randomized, double-blind, placebo-controlled crossover
228 design with five conditions and repeated sampling (baseline plus four hourly draws). The a priori
229 power calculation indicating ~83% power to detect a 1-SD difference assumed a large treatment
230 effect and favorable assumptions regarding between- and within-subject variability. Because
231 repeated measures collected over a short time window are often highly correlated, the effective
232 statistical power in this small sample (n = 5 completing all conditions) is likely lower than the
233 nominal estimate. Accordingly, this study was primarily intended as a pilot to assess safety,
234 tolerability, and variance characteristics rather than to provide definitive evidence of efficacy. All
235 data are presented as a mean percentage EC_{50} with standard error mean . The percentage change
236 in EC_{50} from baseline and the temporal percentage incremental change ((ΔCt-0/C0)) in EC_{50} from
237 baseline were calculated for each time point for each treatment, which are depicted in Figures 2
238 and 3.

For analysis of the PAF EC_{50} data, there were no outliers as shown by examination of studentized residuals for values greater than ± 3. The data was assessed for normality distributed ($p > 0.05$) apart from 1h LDSNR and 3h of HDSNR ($p < 0.05$) as assessed by Shapiro-Wilk's test. Mauchly's test of sphericity indicated that the assumption of sphericity was not met for the two-way interaction, $\chi^2(2) = 67.6$, $p = 0.003$ and Greenhouse-Geisser correction applied. A two-factor analysis of variance (ANOVA; treatment x time) was used with repeated measures on the factor time. The Bonferroni post hoc correction was applied where significant interaction was evident.

For PAF ΔAUC, outliers were assessed via boxplots (values > 1.5 box-lengths). Shapiro–Wilk's test indicated normal distribution for all treatment conditions except HDSNR, which showed marginal deviation ($p = 0.048$). Mauchly's test indicated that the assumption of sphericity was met; therefore, no correction was applied ($\chi^2(9) = 12.52$, $p = 0.281$). Significance was set at $p < 0.05$, and effect sizes are reported as partial eta squared (η_p^2). Post-hoc comparisons were conducted using pairwise contrasts with adjusted p-values where appropriate. All EC_{50} outcomes are presented as percentage change from baseline (mean ± SEM). Statistical results in text are reported as mean differences with 95% confidence intervals (CI)

For thrombin EC_{50}, data screening identified no outliers based on studentized residuals (±3). Normality and sphericity were assessed as described for PAF; sphericity was violated for the treatment × time interaction ($\chi^2(2) = 67.6$, $p = 0.003$), and Greenhouse–Geisser correction was applied. Thrombin ΔAUC analysis identified one outlier in the HDSR condition using the boxplot criterion (>1.5 × IQR). AUC data met normality assumptions, and sphericity was not violated; therefore, no correction was required. Repeated-measures ANOVA was used for both EC_{50} and AUC analyses, with post-hoc pairwise comparisons performed where appropriate. All analyses were conducted using Microsoft Excel (v16.1.1) and SPSS (v30.0.0).

262 **3. Results**

263 *3.1. Postprandial effect of SPL on plasma levels of CRP, glucose, and lipid levels*

264 Baseline plasma biomarkers of the lipid profile TG, TC, HDL-C, LDL-C, glucose, and
265 CRP were within the normal range prior to the study for all participants (Table S1) and no
266 significant change in these biomarkers was observed following ingestion of the SPL or placebo
267 capsules within the timeframe assessed (Figure S1). Cumulative ingestion and exposure should be
268 assessed in a dietary study.

269

270 *3.2. Postprandial effect of SPL on biomarkers of coagulation*

271 Baseline plasma fibrinogen, PT, INR, and APTT were within normal range for all
272 participants prior to the study (Table S2). Furthermore, these parameters did not differ significantly
273 from baseline following ingestion of the SPL or placebo capsules within the timeframe assessed
274 but further study is required for cumalitve exposure (Figure S2).

275

276 *3.3. Postprandial effect of SPL on platelte sensitivity to PAF*

277 Figure 2A depicts the temporal change in PAF EC_{50} for each treatment following ingestion
278 when compared to baseline levels (t = 0). The placebo did not significantly affect PAF EC_{50} at any
279 time during the 4 h postprandial period.

280 Analysis of ΔPAF EC_{50} revealed a significant treatment × time interaction, indicating that
281 the temporal pattern of change differed across treatments ($F(16, 64) = 3.30$, $p \leq .047$, $\eta_p^2 = 0.452$).

Post-hoc pairwise comparisons showed that HDSNR produced significantly greater increases in PAF EC_{50} compared with both placebo and HDSR at specific time points. At 2 h, ΔPAF EC_{50} was higher in HDSNR versus placebo (mean difference 34.16, 95% CI 4.67 to 63.65, p = .029) and versus HDSR (27.9, 95% CI 1.9 to 53.9, p = .039). At 3 h, ΔPAF EC_{50} remained elevated relative to placebo (31.2, 95% CI 7.9 to 54.6, p = .017). Within-condition comparisons showed that HDSNR elicited a significant rise from baseline at both 2 h (31.2, 95% CI 4.89 to 57.5, p = .027) and 3 h (29.3, 95% CI 11.9 to 46.7, p = .007). For the HDSR condition, increases were only evident at 4 h (e.g., 41.1 above baseline, 95% CI 1.17 to 80.9, p = .045).

When collapsed across time, a significant main effect of treatment was also observed ($F(4,16) = 6.75$, p = .015, $\eta_p^2 = 0.628$), driven by a higher mean ΔPAF EC_{50} in HDSNR compared with placebo (22.04, 95% CI 13.7 to 30.4, p = .001). A significant main effect of time indicated that ΔPAF EC_{50} rose above baseline at 3 h across treatments (20.16, 95% CI 3.19 to 37.2, p = .027). For ΔAUC (Figure 2B), repeated-measures ANOVA identified a significant treatment effect ($F(4, 16) = 5.784$, p = .004, $\eta_p^2 = 0.591$). Post-hoc pairwise comparisons showed that HDSNR produced a greater cumulative change in EC_{50} over 0–4 h compared with placebo (mean difference 95.96, 95% CI 55.06–136.7, p = .002). No other pairwise comparisons were significant.



Fig. 2. **(A)** Temporal change in EC_{50} values of PAF-induced platelet aggregation in human platelet-rich plasma across all treatment conditions. Data are presented as mean percentage change

from baseline (ΔC/C EC_{50}; n = 5) with error bars representing the standard error of the mean (SEM). Statistical analysis was performed using a two-factor repeated-measures ANOVA (treatment × time). Where significant interactions were detected, Bonferroni-adjusted pairwise comparisons were applied. *Indicates $p < 0.05$ for significant pairwise differences between treatments at a given time point. **Indicates $p < 0.05$ for significant main effects of treatment or time. An increase in EC_{50} reflects a reduction in platelet sensitivity to PAF. **(B)** Boxplots showing the area-under-the-curve (AUC) for ΔPAF EC_{50} (0–4 h) across all treatment conditions. Boxes represent the interquartile range (IQR), horizontal lines indicate the median, and whiskers show the range excluding outliers; circles represent values >1.5 × IQR identified during outlier screening. AUC data were analysed using a repeated-measures ANOVA after confirming normality (Shapiro–Wilk) and sphericity (Mauchly's test). A significant main effect of treatment was detected ($p < 0.05$), with post-hoc contrasts demonstrating higher ΔAUC in the HDSNR condition compared with placebo. **Abbreviations:** HDSNR, high-dose stomach non-resistant capsule contained 0.5 g of SPL; IQR, interquartile range; HDSR, high-dose stomach resistant capsule contained 0.5 g of SPL; LDSNR, low-dose stomach non-resistant capsule containing 0.25 g of SPL; LDSR, low-dose stomach resistant capsule contained 0.25 g of SPL. PAF, platelet-activating factor; PLAC, placebo control.

3.4. Postprandial effect of SPL on platelet sensitivity to thrombin

Figure 3 depicts the temporal change in thrombin EC_{50} for each treatment following ingestion when compared to baseline measurements (t = 0). The placebo did not significantly affect thrombin EC_{50} at any time in the 4 h postprandial period. Analysis of Δthrombin EC_{50} revealed no significant treatment × time interaction ($F(16, 64) = 3.823$, $p = .050$, $\eta_p^2 = 0.489$), indicating that temporal

342 changes were similar across treatments. When examined independently of time, there was a
343 significant main effect of treatment ($F(4, 16) = 8.965$, $p = .007$, $\eta_p^2 = 0.691$). Post-hoc pairwise
344 comparisons showed that Δthrombin EC_{50} was significantly higher following HDSNR compared
345 with LDSR (mean difference 27.1, 95% CI 10.6–43.6, $p = .008$). A significant main effect of time
346 was also observed ($F(4, 16) = 16.221$, $p < 0.001$, $\eta_p^2 = 0.802$). Compared with baseline, Δthrombin
347 EC_{50} increased significantly at 3 h (36.7, 95% CI 10.8–62.6, $p = .014$) and 4 h (47.7, 95% CI 17.0–
348 78.5, $p = .010$) across treatments. For the ΔAUC analysis, one mild outlier (HDSR) was detected
349 (Figure 3). Repeated-measures ANOVA identified a significant effect of treatment on thrombin
350 ΔAUC ($F(4, 16) = 8.555$, $p < 0.001$, $\eta_p^2 = 0.681$). Post-hoc pairwise comparisons indicated that
351 HDSNR produced a significantly greater cumulative increase in thrombin EC50 over 0–4 h
352 compared with LDSR (mean difference 122.9, 95% CI 53.9–191.9, $p = .006$). No additional
353 pairwise differences reached significance.



Fig. 3. (A) Temporal change in EC_{50} values of thrombin-induced platelet aggregation of human platelet-rich plasma across all treatment conditions. Data are presented as mean percentage change

371 from baseline (ΔC/C EC_{50}; n = 5) with error bars representing the standard error of the mean
372 (SEM). Statistical analysis was performed using a two-factor repeated-measures ANOVA
373 (treatment × time). No significant interaction was detected; however, significant main effects of
374 treatment and time were observed, with post-hoc pairwise comparisons applied where appropriate.
375 Higher EC_{50} values indicate reduced platelet sensitivity to thrombin. **(B)** Boxplots showing the
376 area-under-the-curve (AUC) for Δthrombin EC_{50} (0–4 h) for each treatment. Boxes represent the
377 interquartile range (IQR), horizontal lines indicate the median, and whiskers show the range
378 excluding outliers; circles denote values >1.5 × IQR identified during outlier screening. AUC data
379 were analysed using repeated-measures ANOVA, which revealed a significant main effect of
380 treatment. Post-hoc pairwise comparisons indicated that HDSNR elicited a greater cumulative
381 change in thrombin EC50 compared with LDSR. **Abbreviations:** HDSNR, high-dose stomach
382 non-resistant capsule contained 0.5 g of SPL; IQR, interquartile range; HDSR, high-dose stomach
383 resistant capsule contained 0.5 g of SPL; LDSNR, low-dose stomach non-resistant capsule
384 containing 0.25 g of SPL; LDSR, low-dose stomach resistant capsule contained 0.25 g of SPL.
385 PAF, platelet-activating factor; PLAC, placebo control.

386

387 **4. Discussion**

388 Activation and aggregation of platelets contribute to the inflammatory and thrombotic
389 manifestations of atherosclerosis and CVD [5,6,12]. Dysregulated platelet activity also plays an
390 important role in other pathologies, including type II diabetes mellitus [35] and cancer [36].
391 Repetitive activation of platelets and plasmatic coagulation during the postprandial period has
392 further been implicated in the initiation, development, and progression of atherosclerosis [2,21,37].
393 These mechanisms highlight the importance of identifying bioactive molecules and natural

394 products capable of attenuating platelet activation, with the aim of developing novel supplements
395 and nutraceuticals with potential cardioprotective properties. While there are several avenues of
396 potential research to explore, including dietary components of the Mediterranean diet capable of
397 reducing postprandial platelet sensitivity to PAF in healthy individuals and patients with metabolic
398 syndrome [38,39].

399 Marine-derived polar lipids represent one such promising class of bioactives. Previous in
400 vitro studies have demonstrated that salmon polar lipid (SPL) extracts contain bioactive molecules
401 with anti-PAF and anti-thrombin activities [25,27,28]. A broader body of work from our group and
402 others has shown that marine polar lipids exhibit diverse anti-inflammatory and cardioprotective
403 effects [17,23,27,31,40,41], including anti-atherogenic actions in platelets and various cell types both
404 *in vitro* and *in vivo* [42,43]. While natural antiplatelet nutraceuticals such as FruitFlow™, a water
405 soluble (lipid-free) tomato-based supplement shown to beneficially affect postprandial ADP-
406 induced platelet aggregation [44], have reached commercial use, targeted clinical work examining
407 marine polar lipid preparations remains limited.

408 In this context, the present pilot study provides the first in vivo indication that SPL
409 ingestion may modestly reduce platelet sensitivity to both PAF and thrombin in healthy subjects.
410 Among the five postprandial trials tested, the high-dose non–stomach-resistant capsule (HDSNR)
411 produced the clearest reductions in platelet sensitivity, with significant increases in EC_{50} for PAF
412 at 2–3 h and for thrombin at 3–4 h post-ingestion. The stomach-resistant formulation (HDSR)
413 generated similar but delayed effects, suggesting that the timing of polar lipid release plays a
414 crucial role in determining the onset of antiplatelet activity. The low-dose capsules produced more
415 modest or inconsistent responses. Despite the small sample size, these findings support the concept
416 that SPL-derived polar lipids acutely modulate platelet reactivity, potentially through interactions

417 with the PAF-R and PAR receptors. The stronger and earlier effect observed with HDSNR is
418 consistent with more rapid release and absorption of bioactive lipids, whereas the attenuated and
419 delayed effect of HDSR suggests slower release in the gastrointestinal tract.

420 Importantly, these antiplatelet effects occurred without measurable alterations in key
421 haemostatic biomarkers (fibrinogen, PT, APTT, INR). Monitoring such biomarkers is essential
422 when evaluating novel antiplatelet agents to ensure that modulation of platelet sensitivity does not
423 translate into increased bleeding risk [45,46]. Notably, the reduction of the sensitivity of platelets
424 against both PAF and thrombin during both high-dose trials does not seem to affect coagulation
425 biomarker (Fibrinogen, PT, APTT, and INR). These results further suggest that the observed
426 favorable postprandial antiplatelet effects against both PAF and thrombin do not postprandially
427 increase the risk of bleeding, even when supplements containing high doses of the SPL were
428 administrated during the HDSNR and HDSR trials. These findings support the notion that marine
429 phospholipid supplements are safe for consumption [31]. However, cumulative intake and long-
430 term exposure must be monitored by conducting a dietary intervention study to ensure safety.

431 Plasma fibrinogen, an acute-phase reactant associated with cardiovascular risk and platelet
432 aggregation [46], also remained unchanged. The absence of fibrinogen fluctuations likely reflects
433 the healthy status of the cohort, as supported by consistently low CRP values (<5 mg/L) throughout
434 the study. Similarly, postprandial glucose and lipid levels (TC, HDL-C, LDL-C, TG) remained
435 stable, which is desirable given that postprandial hyperglycemia and lipemia can augment platelet
436 reactivity and cardiovascular risk [20,47,48]. The stability of these markers likely reflects the healthy
437 metabolic profile of participants at baseline.

438

439 The earlier and more pronounced antiplatelet response observed in the HDSNR trial
440 compared with the HDSR trial likely reflects differences in capsule disintegration and bioactive
441 lipid release. Non-resistant capsules permit immediate release in the stomach, whereas resistant
442 capsules delay release until later digestive stages. These release profiles may have implications for
443 optimizing postprandial timing and therapeutic efficacy with further considerations for circadian
444 rhythms [49,50]. Nonetheless, the overall magnitude of the antiplatelet response was modest and
445 must be interpreted with caution, as intra- and inter-individual variability may have influenced
446 outcomes in this small cohort. Platelet function is known to vary with diet, ethnicity, sex, and other
447 factors [51]. Furthermore, a postprandial assessment is required to determine how long the
448 postprandial effects lasts, to inform for dosage in further studies.

449 While consumption of the capsule in this trial appears to be safe and did not increase the
450 risk of bleeding following acute exposure, further long-term studies are required to confirm these
451 observations. Furthermore, we did not observe how long the antiplatelet effect would last
452 postprandially. Therefore, additional research is required to determine whether a repeated dose
453 schedule is required. Previous studies of omega-3 fatty acid preparations, which carry similar fatty
454 acids but in neutral forms, have shown that the antiplatelet effects may last up to hours post
455 ingestion. However, it is difficult to determine whether this would be a similar response using PL
456 supplements and our findings would suggest that the encapsulation method would be important to
457 consider.

458 Additionally, this study used a relatively low (0.25 g) and high-dose (0.5 g) version of the
459 capsule, similar trials using fish oils high in EPA and DHA known to have antithrombotic effects
460 previously administered doses in excess of 5g [52]. A conservative amount of fish oil in the form
461 of polar lipids used was chosen for these trials due to the greater reported bioavailability and

462 bioactivity of polar lipids. Future work should evaluate higher SPL doses (e.g., 1 g) to better
463 characterize dose–response relationships. Tolerability was good in this study, with no
464 gastrointestinal symptoms or vasoconstrictive adverse events reported. However, side effects are
465 possible and fish oil supplements have been associated with diarrhea, but these side effects tend to
466 be associated with large doses of fish oil [52]. Fishy breath or belching is also a possible side effect
467 of fish oil supplement intake. Indeed, the salmon capsules used in this study were not deodorized,
468 as is common for similar fish supplements. We chose not to undertake this step due to potential
469 degradation of the lipid content [53]. Therefore, dietary intervention studies should assess for these
470 common side effects to improve formulation of the capsule.

471 Lastly, the diet of fish influences the fatty acid and polar lipid composition of the flesh,
472 which in turn affects the composition of fish oils [54,55]. This opens the field to opportunities for
473 tailored polar lipid compositions as a therapeutic or as a liposomal carrier [56] for other drugs
474 through modulation of the diet in aquaculture setting.

475

476 **5. Conclusions**

477 This is the first placebo-controlled study reporting a modest favorable outcome of the
478 administration of a novel food supplement containing bioactive SPL, with respect to postprandial
479 platelet sensitivity against PAF and thrombin and its related cardiovascular risk in healthy human
480 subjects. This pilot study provides data and the rationale to support the development of further
481 large long-term trials to confirm these findings in both healthy subjects and cardiovascular patients
482 to evaluate the long-term effects, safety, tolerability, and cardioprotective properties of this novel
483 supplement.

484

Supplementary Materials: Table S1: Participant baseline physical and haematological characteristics; Table S2: Participant baseline biochemical characteristics. Figure S1: Postprandial effect of SPL on the plasma levels of triglycerides, total cholesterol, HDL, and LDL cholesterol and glucose; Figure S2: Postprandial effect of SPL on blood coagulation biomarkers.

Author Contributions: Conceptualization, I.Z., A.T., P.J. and R.L.; methodology, R.L. and A.T.; software, R.L.; validation, P.J., I.Z. and R.L.; formal analysis, A.T. and R.L.; investigation, A.T. and R.L..; resources, P.J.I.Z.; data and curation, R.L. and P.J.; writing—original draft preparation, R.L. and A.T.; writing—review and editing, R.L., A.T., P.J. and I.Z.; visualization, A.T., R.L. and P.J.; supervision, P.J. and I.Z.; project administration. A.T. and R.L.; funding acquisition, P.J., R.L. and I.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Enterprise Ireland (grant reference: IP 2017 0518).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Faculty of Science & Engineering Research Ethics Committee of the University of Limerick (UL Ethics Approval Number: 2017_10_10_S&E).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data is available from the authors without reservation.

Acknowledgments: The authors are grateful to the volunteers who took part in the study, to Elaine Ahern for her phlebotomy support, and to Dr Emmet Kerrin at Treaty Medical, Limerick. The authors acknowledge the support of Lifes2good, Marine Harvest, and Mowi Ireland for their contributions. We would also like to thank the Departments of Physical Education and Sports Science and the Biological Sciences at the University of Limerick, Ireland, for their continued support. Finally, we are grateful to Patricia Kennedy, Carolyn Holt, and colleagues at the laboratories of the University Hospital Limerick for analytical support.

Conflicts of Interest: The authors declare no conflict of interest. The grant providers, Enterprise Ireland IP 2017 0508, had no role in the design of the study, in the collection, analyses or interpretation of the data or in the writing of the manuscript.

References:

1. P. Libby; Ridker, P.M.; Hansson, G.K. Inflammation in Atherosclerosis: From Pathophysiology to Practice. *J Am Coll Cardiol* 2009, *54*, 2129-2138, doi:https://doi.org/10.1016/j.jacc.2009.09.009.
2. R. Lordan; Tsoupras, A.; Zabetakis, I. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. *Blood Reviews* 2021, *45*, 100694, doi:https://doi.org/10.1016/j.blre.2020.100694.
3. P. Libby. Inflammation in Atherosclerosis—No Longer a Theory. *Clinical Chemistry* 2020, *67*, 131-142, doi:10.1093/clinchem/hvaa275.
4. P. Kong; Cui, Z.-Y.; Huang, X.-F.; Zhang, D.-D.; Guo, R.-J.; Han, M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. *Signal Transduction and Targeted Therapy* 2022, *7*, 131, doi:10.1038/s41392-022-00955-7.
5. K.Y. Stokes; Granger, D.N. Platelets: a critical link between inflammation and microvascular dysfunction. *The Journal of Physiology* 2012, *590*, 1023-1034, doi:10.1113/jphysiol.2011.225417.
6. R. Huilcaman; Venturini, W.; Fuenzalida, L.; Cayo, A.; Segovia, R.; Valenzuela, C.; Brown, N.; Moore-Carrasco, R. Platelets, a key cell in inflammation and atherosclerosis progression. *Cells* 2022, *11*, doi:10.3390/cells11061014.

538 7. C. Bakogiannis; Sachse, M.; Stamatelopoulos, K.; Stellos, K. Platelet-derived
539 chemokines in inflammation and atherosclerosis. *Cytokine* 2019, *122*, 154157,
540 doi:https://doi.org/10.1016/j.cyto.2017.09.013.
541 8. N.E. Tsopanoglou; Maragoudakis, M.E. Thrombin's central role in angiogenesis and
542 pathophysiological processes. *European Cytokine Network* 2009, *20*, 171-179.
543 9. Z. Li; Delaney, M.K.; O'Brien, K.A.; Du, X. Signaling during platelet adhesion and
544 activation. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2010, *30*, 2341-2349,
545 doi:10.1161/ATVBAHA.110.207522.
546 10. G.A. Zimmerman; McIntyre, T.M.; Prescott, S.M.; Stafforini, D.M. The platelet-
547 activating factor signaling system and its regulators in syndromes of inflammation and
548 thrombosis. *Critical care medicine* 2002, *30*, S294-S301.
549 11. R. Lordan; Tsoupras, A.; Zabetakis, I.; Demopoulos, A.C. Forty years since the structural
550 elucidation of platelet-activating factor (PAF): Historical, current, and future research
551 perspectives. *Molecules* 2019, *24*, doi:doi:10.3390/molecules24234414.
552 12. N. Jaberi; Soleimani, A.; Pashirzad, M.; Abdeahad, H.; Mohammadi, F.; Khoshakhlagh,
553 M.; Khazaei, M.; Ferns, G.A.; Avan, A.; Hassanian, S.M. Role of thrombin in the
554 pathogenesis of atherosclerosis. *Journal of Cellular Biochemistry* 2019, *120*, 4757-4765,
555 doi:10.1002/jcb.27771.
556 13. F.K. Keating; Schneider, D.J. The influence of platelet activating factor on the effects of
557 platelet agonists and antiplatelet agents in vitro. *Journal of Thrombosis and Thrombolysis*
558 2009, *28*, 38-45, doi:10.1007/s11239-008-0239-5.
559 14. V.O. Melnikova; Villares, G.J.; Bar-Eli, M. Emerging roles of PAR-1 and PAFR in
560 melanoma metastasis. *Cancer Microenvironment* 2008, *1*, 103-111, doi:10.1007/s12307-
561 008-0002-7.
562 15. E. Yu; Malik, V.S.; Hu, F.B. Cardiovascular disease prevention by diet modification:
563 JACC Health Promotion Series. *Journal of the American College of Cardiology* 2018, *72*,
564 914-926, doi:doi:10.1016/j.jacc.2018.02.085.
565 16. P. Wang; Song, M.; Eliassen, A.H.; Wang, M.; Fung, T.T.; Clinton, S.K.; Rimm, E.B.; Hu,
566 F.B.; Willett, W.C.; Tabung, F.K., et al. Optimal dietary patterns for prevention of chronic
567 disease. *Nature Medicine* 2023, *29*, 719-728, doi:10.1038/s41591-023-02235-5.
568 17. T. Nomikos; Fragopoulou, E.; Antonopoulou, S.; Panagiotakos, D.B. Mediterranean diet
569 and platelet-activating factor; a systematic review. *Clinical Biochemistry* 2018,
570 https://doi.org/10.1016/j.clinbiochem.2018.08.004,
571 doi:https://doi.org/10.1016/j.clinbiochem.2018.08.004.
572 18. J.H. O'Keefe; Bell, D.S.H. Postprandial hyperglycemia/hyperlipidemia (postprandial
573 dysmetabolism) is a cardiovascular risk factor. *The American Journal of Cardiology*
574 2007, *100*, 899-904, doi:http://dx.doi.org/10.1016/j.amjcard.2007.03.107.
575 19. E.J.P. de Koning; Rabelink, T.J. Endothelial function in the post-prandial state.
576 *Atherosclerosis Supplement* 2002, *3*, 11-16, doi:http://dx.doi.org/10.1016/S1567-
577 5688(01)00008-3.
578 20. D.A. Hyson; Paglieroni, T.G.; Wun, T.; Rutledge, J.C. Postprandial Lipemia is Associated
579 With Platelet and Monocyte Activation and Increased Monocyte Cytokine Expression in
580 Normolipemic Men. *Clinical and Applied Thrombosis/Hemostasis* 2002, *8*, 147-155,
581 doi:10.1177/107602960200800211.
582 21. A. Mikellidi; Nomikos, T. Postprandial activation of platelets as a possible mechanism
583 for the development of atherosclerosis. *Hellenic Journal of Atherosclerosis* 2016, *7*.

22. M.N. Xanthopoulou; Kalathara, K.; Melachroinou, S.; Arampatzi-Menenakou, K.; Antonopoulou, S.; Yannakoulia, M.; Fragopoulou, E. Wine consumption reduced postprandial platelet sensitivity against platelet activating factor in healthy men. *European Journal of Nutrition* 2017, *56*, 1485-1492, doi:doi:10.1007/s00394-016-1194-0.
23. C. Caffrey; Leamy, A.; O'Sullivan, E.; Zabetakis, I.; Lordan, R.; Nasopoulou, C. Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids. *Marine Drugs* 2023, *21*, 549.
24. R. Tummala; Ghosh, R.K.; Jain, V.; Devanabanda, A.R.; Bandyopadhyay, D.; Deedwania, P.; Aronow, W.S. Fish Oil and Cardiometabolic Diseases: Recent Updates and Controversies. *The American Journal of Medicine* 2019, *132*, 1153-1159, doi:https://doi.org/10.1016/j.amjmed.2019.04.027.
25. A. Tsoupras; Lordan, R.; Shiels, K.; Saha, S.K.; Nasopoulou, C.; Zabetakis, I. In vitro antithrombotic properties of salmon (*Salmo salar*) phospholipids in a novel food-grade extract. *Marine Drugs* 2019, *17*, 62, doi:https://doi.org/10.3390/md17010062.
26. A.S. Chopra; Lordan, R.; Horbańczuk, O.K.; Atanasov, A.G.; Chopra, I.; Horbańczuk, J.O.; Jóźwik, A.; Huang, L.; Pirgozliev, V.; Banach, M., et al. The current use and evolving landscape of nutraceuticals. *Pharma. Res.* 2022, *175*, 106001, doi:https://doi.org/10.1016/j.phrs.2021.106001.
27. A. Tsoupras; O'Keeffe, E.; Lordan, R.; Redfern, S.; Zabetakis, I. Bioprospecting for antithrombotic polar lipids from salmon, herring, and boarfish by-products. *Foods* 2019, *8*, 416, doi:https://doi.org/10.3390/foods8090416.
28. A. Tsoupras; Lordan, R.; Demuru, M.; Shiels, K.; Saha, S.K.; Nasopoulou, C.; Zabetakis, I. Structural elucidation of Irish organic farmed salmon (*Salmo salar*) polar lipids with antithrombotic activities. *Marine Drugs* 2018, *16*, 176, doi:https://doi.org/10.3390/md16060176.
29. H. Cao; Chen, S.-F.; Wang, Z.-C.; Dong, X.-J.; Wang, R.-R.; Lin, H.; Wang, Q.; Zhao, X.-J. Intervention of 4% salmon phospholipid on metabolic syndrome in mice based on colonic lipidomics analysis. *Journal of the Science of Food and Agriculture* 2022, *102*, 3088-3098, doi:https://doi.org/10.1002/jsfa.11649.
30. R. Adili; Hawley, M.; Holinstat, M. Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids. *Prostaglandins & Other Lipid Mediators* 2018, *139*, 10-18, doi:https://doi.org/10.1016/j.prostaglandins.2018.09.005.
31. R. Lordan; Redfern, S.; Tsoupras, A.; Zabetakis, I. Inflammation and cardiovascular disease: are marine phospholipids the answer? *Food Funct.* 2020, *11*, 2861 - 2885, doi:https://doi.org/10.1039/C9FO01742A.
32. E.M. Bachmair; Ostertag, L.M.; Zhang, X.; de Roos, B. Dietary manipulation of platelet function. *Pharmacology & Therapeutics* 2014, *144*, 97-113, doi:https://doi.org/10.1016/j.pharmthera.2014.05.008.
33. Health Service Executive Ireland. Healthy food for life guidelines. Availabe online: http://www.hse.ie/eng/about/Who/healthwellbeing/Our-Priority-Programmes/HEAL/Healthy-Eating-Guidelines/ (accessed on accessed on 17 January 2018).
34. A. Tsoupras; Zabetakis, I.; Lordan, R. Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function *in vitro*. *MethodsX* 2019, *6*, 63-70, doi:https://doi.org/10.1016/j.mex.2018.12.012.

35. L. Pretorius; Thomson, G.J.A.; Adams, R.C.M.; Nell, T.A.; Laubscher, W.A.; Pretorius, E. Platelet activity and hypercoagulation in type 2 diabetes. *Cardiovascular Diabetology* 2018, *17*, 141, doi:10.1186/s12933-018-0783-z.
36. A. Contursi; Grande, R.; Dovizio, M.; Bruno, A.; Fullone, R.; Patrignani, P. Platelets in cancer development and diagnosis. *Biochem Soc Trans* 2018, *46*, 1517-1527, doi:10.1042/bst20180159.
37. A.K. Duttaroy. Postprandial activation of hemostatic factors: Role of dietary fatty acids. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 2005, *72*, 381-391, doi:10.1016/j.plefa.2005.03.003.
38. E. Fragopoulou; Detopoulou, P.; Nomikos, T.; Pliakis, E.; Panagiotakos, D.B.; Antonopoulou, S. Mediterranean wild plants reduce postprandial platelet aggregation in patients with metabolic syndrome. *Metabolism* 2012, *61*, 325-334.
39. M.N. Xanthopoulou; Kalathara, K.; Melachroinou, S.; Arampatzi-Menenakou, K.; Antonopoulou, S.; Yannakoulia, M.; Fragopoulou, E. Wine consumption reduced postprandial platelet sensitivity against platelet activating factor in healthy men. *European Journal of Nutrition* 2016, http://dx.doi.org/10.1007/s00394-016-1194-0, 1-8, doi:http://dx.doi.org/10.1007/s00394-016-1194-0.
40. F. Petsini; Ntzouvani, A.; Detopoulou, M.; Papakonstantinou, V.D.; Kalogeropoulos, N.; Fragopoulou, E.; Nomikos, T.; Kontogianni, M.D.; Antonopoulou, S. Consumption of Farmed Fish, Fed with an Olive-Pomace Enriched Diet, and Its Effect on the Inflammatory, Redox, and Platelet-Activating Factor Enzyme Profile of Apparently Healthy Adults: A Double-Blind Randomized Crossover Trial. *Foods* 2022, *11*, 2105.
41. E. Sioriki; Smith, T.K.; Demopoulos, C.A.; Zabetakis, I. Structure and cardioprotective activities of polar lipids of olive pomace, olive pomace-enriched fish feed and olive pomace fed gilthead sea bream (*Sparus aurata*). *Food Res. Int.* 2016, *83*, 143-151, doi:http://dx.doi.org/10.1016/j.foodres.2016.03.015.
42. C. Nasopoulou; Karantonis, H.C.; Perrea, D.N.; Theocharis, S.E.; Iliopoulos, D.G.; Demopoulos, C.A.; Zabetakis, I. In vivo anti-atherogenic properties of cultured gilthead sea bream (*Sparus aurata*) polar lipid extracts in hypercholesterolaemic rabbits. *Food Chemistry* 2010, *120*, 831-836, doi:http://dx.doi.org/10.1016/j.foodchem.2009.11.023.
43. C. Nasopoulou; Tsoupras, A.B.; Karantonis, H.C.; Demopoulos, C.A.; Zabetakis, I. Fish polar lipids retard atherosclerosis in rabbits by down-regulating PAF biosynthesis and up-regulating PAF catabolism. *Lipids in Health and Disease* 2011, *10*, 1-18, doi:doi:10.1186/1476-511X-10-213.
44. N. O'Kennedy; Crosbie, L.; van Lieshout, M.; Broom, J.I.; Webb, D.J.; Duttaroy, A.K. Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. *The American Journal of Clinical Nutrition* 2006, *84*, 570-579.
45. J.M. Walenga; Hoppensteadt, D.A. Monitoring the new antithrombotic drugs. In Proceedings of Seminars in Thrombosis and Hemostasis; pp. 683-695.
46. W.B. Kannel. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. *Lipids* 2005, *40*, 1215-1220, doi:10.1007/s11745-005-1488-8.
47. D. Hyson; Rutledge, J.C.; Berglund, L. Postprandial lipemia and cardiovascular disease. *Current Atherosclerosis Reports* 2003, *5*, 437-444, doi:http://dx.doi.org/10.1007/s11883-003-0033-y.

48. M. Shimodaira; Niwa, T.; Nakajima, K.; Kobayashi, M.; Hanyu, N.; Nakayama, T. Correlation between mean platelet volume and blood glucose levels after oral glucose loading in normoglycemic and prediabetic Japanese subjects. *Journal of Diabetes Investigation* 2014, *5*, 66-71, doi:10.1111/jdi.12117.
49. C.T. Butler; Rodgers, A.M.; Curtis, A.M.; Donnelly, R.F. Chrono-tailored drug delivery systems: recent advances and future directions. *Drug Delivery and Translational Research* 2024, *14*, 1756-1775, doi:10.1007/s13346-024-01539-4.
50. G.K. Paschos; Lordan, R.; FitzGerald, G.A. Intersection of sex and circadian Biology. *Current Opinion in Physiology* 2025.
51. C.H. Miller; Rice, A.S.; Garrett, K.; Stein, S.F. Gender, race and diet affect platelet function tests in normal subjects, contributing to a high rate of abnormal results. *British journal of haematology* 2014, *165*, 842-853, doi:10.1111/bjh.12827.
52. C. Skarke; Alamuddin, N.; Lawson, J.A.; Li, X.; Ferguson, J.F.; Reilly, M.P.; FitzGerald, G.A. Bioactive products formed in humans from fish oils. *Journal of Lipid research* 2015, *56*, 1808-1820.
53. V. Fournier; Destaillats, F.; Juanéda, P.; Dionisi, F.; Lambelet, P.; Sébédio, J.-L.; Berdeaux, O. Thermal degradation of long-chain polyunsaturated fatty acids during deodorization of fish oil. *European Journal of Lipid Science and Technology* 2006, *108*, 33-42, doi:https://doi.org/10.1002/ejlt.200500290.
54. B.K. Hundal; Liland, N.S.; Rosenlund, G.; Bou, M.; Stubhaug, I.; Sissener, N.H. Increasing dietary n-6 fatty acids while keeping n-3 fatty acids stable decreases EPA in polar lipids of farmed Atlantic salmon (Salmo salar). *British Journal of Nutrition* 2021, *125*, 10-25, doi:10.1017/S0007114520002494.
55. K. Kousoulaki; Østbye, T.-K.K.; Krasnov, A.; Torgersen, J.S.; Mørkøre, T.; Sweetman, J. Metabolism, health and fillet nutritional quality in Atlantic salmon (Salmo salar) fed diets containing n-3-rich microalgae. *Journal of Nutritional Science* 2015, *4*, e24, doi:10.1017/jns.2015.14.
56. M. Gerlei; Pruvost, L.; Linder, M. Salmon and krill phospholipids: Two nanocarriers with interesting physico-chemical properties. *Biochimie* 2025, *239*, 19-29, doi:https://doi.org/10.1016/j.biochi.2025.09.010.